Medicare’s “bundling” policy, intended to reduce drug spending in the dialysis setting, has turned pricing pressure into a choke hold in kidney disease. The cost containment policies for intravenous drugs went into effect Jan. 1, 2011, making the year a tense one for some drugmakers working in the therapeutic area. And the measures are set to extend to oral drugs in 2014, which means pricing pressure in dialysis isn’t going to diminish anytime soon.
[Sidebar#2012800128]
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?